Characteristics and outcomes of cancer patients who develop pulmonary embolism: A cross-sectional study.

D-dimer albumin cancer carcinoembryonic antigen chemotherapy lactic acid platelets pulmonary embolism

Journal

Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
May 2022
Historique:
received: 16 02 2022
accepted: 17 03 2022
entrez: 2 5 2022
pubmed: 3 5 2022
medline: 3 5 2022
Statut: ppublish

Résumé

Pulmonary embolism (PE), along with deep vein thrombosis, are collectively known as venous thromboembolism (VTE). Predisposing factors for PE include post-operative conditions, pregnancy, cancer and an advanced age; of note, a number of genetic mutations have been found to be associated with an increased risk of PE. The association between cancer and VTE is well-established, and cancer patients present a higher risk of a thrombotic event compared to the general population. In addition, PE is a significant cause of morbidity and mortality among cancer patients. The aim of the present study was to illustrate the clinical characteristics, laboratory findings, radiology features and outcomes of cancer patients who developed PE, collected from an anticancer hospital. For this purpose, adult cancer patients diagnosed with PE by imaging with computed tomography pulmonary angiography were enrolled. The following data were recorded: Demographics, comorbidities, type of cancer, time interval between cancer diagnosis and PE occurrence, the type of therapy received and the presence of metastases, clinical signs and symptoms, predisposing factors for PE development, laboratory data, radiological findings, electrocardiography findings, and the type of therapy received for PE and outcomes in a follow-up period of 6 months. In total, 60 cancer patients were enrolled. The majority of the cancer patients were males. The most common type of cancer observed was lung cancer. The majority of cases of PE occurred within the first year from the time of cancer diagnosis, while the majority of patients had already developed metastases. In addition, the majority of cancer patients had received chemotherapy over the past month, while they were not receiving anticoagulants and had central obstruction. A large proportion of patients had asymptomatic PE. The in-hospital mortality rate was 13.3% and no relapse or mortality were observed during the follow-up period. The present study demonstrates that elevated levels of lactic acid and an increased platelet count, as well as low serum levels of carcinoembryonic antigen, albumin and D-dimer, may be potential biomarkers for asymptomatic PE among cancer patients.

Identifiants

pubmed: 35496573
doi: 10.3892/ol.2022.13288
pii: OL-23-05-13288
pmc: PMC9019772
doi:

Types de publication

Journal Article

Langues

eng

Pagination

168

Informations de copyright

Copyright: © Chlapoutakis et al.

Déclaration de conflit d'intérêts

DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article. The author authors declare that they have no competing interests.

Références

Jpn J Clin Oncol. 2020 Oct 22;50(11):1246-1253
pubmed: 32715307
Arch Intern Med. 2008 Oct 27;168(19):2131-6
pubmed: 18955643
Thromb Haemost. 2009 Jan;101(1):197-200
pubmed: 19132208
Croat Med J. 2018 Aug 31;59(4):149-155
pubmed: 30203628
J Clin Med. 2020 Mar 30;9(4):
pubmed: 32235490
Oncologist. 2016 Feb;21(2):252-7
pubmed: 26764252
Acta Med Port. 2015 Jul-Aug;28(4):463-8
pubmed: 26574981
Eur Respir J. 2017 Jan 4;49(1):
pubmed: 28052954
Acad Emerg Med. 2011 Aug;18(8):830-5
pubmed: 21843218
Ann Emerg Med. 2013 Mar;61(3):330-8
pubmed: 23306454
Br Med J. 1971 Jun 19;2(5763):681-4
pubmed: 5556052
Cancers (Basel). 2018 Oct 11;10(10):
pubmed: 30314362
Asian Pac J Cancer Prev. 2012;13(4):1311-5
pubmed: 22799324
Pathol Oncol Res. 2018 Apr;24(2):283-287
pubmed: 28470575
J Thromb Haemost. 2004 Aug;2(8):1247-55
pubmed: 15304025
Clin Adv Hematol Oncol. 2017 Aug;15(8):580-583
pubmed: 28949944
Radiology. 2006 Jul;240(1):246-55
pubmed: 16684921
J Cancer Res Ther. 2019;15(2):344-349
pubmed: 30964109
Oncotarget. 2017 Jun 20;8(25):41412-41421
pubmed: 28575869
Support Care Cancer. 2021 Mar;29(3):1293-1302
pubmed: 32621266
Am J Hematol. 2019 Jan;94(1):21-28
pubmed: 30252149
Technol Cancer Res Treat. 2017 Dec;16(6):1130-1135
pubmed: 29332446
Medicina (Kaunas). 2020 Jan 09;56(1):
pubmed: 31936687
J Thromb Thrombolysis. 2020 May;49(4):572-577
pubmed: 31786713
Curr Opin Oncol. 2020 Jul;32(4):289-294
pubmed: 32541315
JAMA. 2005 Feb 9;293(6):715-22
pubmed: 15701913
Br J Radiol. 2018 Jul;91(1088):20170806
pubmed: 29688026
Vasc Health Risk Manag. 2011;7:153-8
pubmed: 21468175
J Am Coll Cardiol. 2010 Jun 29;56(1):1-7
pubmed: 20620709
Med Clin North Am. 2019 May;103(3):549-564
pubmed: 30955521
Thromb Res. 2014 May;133 Suppl 2:S172-8
pubmed: 24862140

Auteurs

Serafeim Chlapoutakis (S)

Department of Thoracic Surgery, Agios Savvas Hospital, 11522 Athens, Greece.

Vasiliki Epameinondas Georgakopoulou (VE)

Pulmonology Department, Laiko General Hospital, 11527 Athens, Greece.

Nikolaos Trakas (N)

Department of Biochemistry, Sismanogleio Hospital, 15126 Athens, Greece.

Georgios Kouvelos (G)

Department of Vascular Surgery, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41334 Larissa, Greece.

Petros Papalexis (P)

Unit of Endocrinology, First Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Department of Biomedical Sciences, University of West Attica, 12243 Athens, Greece.

Christos Damaskos (C)

Renal Transplantation Unit, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Pagona Sklapani (P)

Department of Cytology, Mitera Hospital, 15123 Athens, Greece.

Anastasios Grivas (A)

Second Department of Medical Oncology, Agios Savvas Hospital, 11522 Athens, Greece.

Panagiotis Gouveris (P)

Second Department of Medical Oncology, Agios Savvas Hospital, 11522 Athens, Greece.

Dimitrios Tryfonopoulos (D)

Second Department of Medical Oncology, Agios Savvas Hospital, 11522 Athens, Greece.

Alexandros Tzovaras (A)

First Department of Medical Oncology, Agios Savvas Hospital, 11522 Athens, Greece.

Gerasimos Ardavanis-Loukeris (G)

First Department of Medical Oncology, Agios Savvas Hospital, 11522 Athens, Greece.

Elissavet Grouzi (E)

Department of Transfusion Service and Clinical Hemostasis, Agios Savvas Hospital, 11522 Athens, Greece.

Demetrios A Spandidos (DA)

Laboratory of Clinical Virology, Medical School, University of Crete, 71003 Heraklion, Greece.

Miltiadis Matsagkas (M)

Department of Vascular Surgery, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41334 Larissa, Greece.

Classifications MeSH